ATR logo

AptarGroup, Inc. Stock Price

NYSE:ATR Community·US$8.0b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 12 Fair Values set on narratives written by author

ATR Share Price Performance

US$127.69
-32.36 (-20.22%)
US$161.43
Fair Value
US$127.69
-32.36 (-20.22%)
20.9% undervalued intrinsic discount
US$161.43
Fair Value
Price US$127.69
AnalystConsensusTarget US$161.43
AnalystHighTarget US$211.14
AnalystLowTarget US$144.00

ATR Community Narratives

·
Fair Value US$161.43 20.9% undervalued intrinsic discount

ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions

0users have liked this narrative
0users have commented on this narrative
7users have followed this narrative
·
Fair Value US$211.14 39.5% undervalued intrinsic discount

Rising Global Wellness Trends Will Unlock Biologics And Smart Packaging

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$144 11.3% undervalued intrinsic discount

European Destocking And Litigation Will Mar Results But Spur Recovery

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US$161.43
20.9% undervalued intrinsic discount
Revenue
5.14% p.a.
Profit Margin
9.97%
Future PE
26.74x
Price in 2029
US$196.16

Trending Discussion

Updated Narratives

ATR logo

ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential

Fair Value: US$211.14 39.5% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ATR logo

ATR: Nasal Therapies And Share Buybacks Will Support Future Upside

Fair Value: US$144 11.3% undervalued intrinsic discount
1 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ATR logo

ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns

Fair Value: US$161.43 20.9% undervalued intrinsic discount
7 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Excellent balance sheet established dividend payer.

2 Risks
4 Rewards

AptarGroup, Inc. Key Details

US$3.9b

Revenue

US$2.5b

Cost of Revenue

US$1.4b

Gross Profit

US$1.0b

Other Expenses

US$386.7m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Jul 30, 2026
6.06
36.67%
9.98%
51.2%
View Full Analysis

About ATR

Founded
1992
Employees
14000
CEO
Stephan Tanda
WebsiteView website
www.aptar.com

AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations, as well as closures, such as dispensing and non-dispensing solutions that enable product delivery without removal of the cap and used across various consumer end markets. The company also offers aerosol valves used in pressurized containers and continuous spray and metered-dose valves for pharmaceutical, personal care, and household applications; elastomeric primary packaging components; active material science solutions; and digital health solutions. The company primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

Recent ATR News & Updates

Seeking Alpha Jun 29

AptarGroup Has Fallen Enough (Rating Upgrade)

Summary AptarGroup is upgraded from 'sell' to 'hold' as valuation improves after a significant share price decline. ATR's Q1 revenue rose 10.8% to $982.9M, but most growth was driven by FX and acquisitions, not organic expansion. Cash flows and EBITDA improved despite margin compression and net profit declines, particularly due to Beauty segment strength. ATR trades at a premium to peers, justified by its niche positioning, but not enough for a 'buy' rating. Read the full article on Seeking Alpha
Analysis Article Jun 18

AptarGroup (ATR) Stock Could Be 25.5% Undervalued on Its Drug Delivery Growth Narrative

Why AptarGroup Stock Is Back On Investor Radars AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year. For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations. See our latest analysis for AptarGroup. With the share...
Narrative Update Jun 17

ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential

The analyst price target for AptarGroup has been adjusted slightly to $211.14 from $211.25. Analysts cite updated assumptions for revenue growth, profit margins and the future P/E multiple as the main drivers of the change.

Recent updates

No updates